Common Contracts
7 similar Employment Agreement contracts by Compass Therapeutics, Inc., Fusion Pharmaceuticals Inc., Magenta Therapeutics, Inc., resTORbio, Inc.
EMPLOYMENT AGREEMENTEmployment Agreement • March 21st, 2024 • Compass Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”), dated as of January 8, 2024, is made between Compass Therapeutics, Inc., a Delaware corporation (including all wholly-owned subsidiaries of Compass Therapeutics, Inc., the “Company”), and Vered Bisker-Leib (the “Executive”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), effective as of the Effective Date (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any offer letter, employment agreement or severance agreement, including, without limitation, the Employment Agreement dated as of April 14, 2021, between the Company and the Executive.
EMPLOYMENT AGREEMENTEmployment Agreement • March 16th, 2023 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
This Employment Agreement (“Agreement”) is made between Fusion Pharmaceuticals Inc. (“Parent Company”), Fusion Pharmaceuticals US Inc., a Delaware corporation and US subsidiary of the Parent Company (the “Company”), and Dmitri Bobilev (the “Executive”) and is effective as of November 7, 2022, or such other date as may be agreed upon by the parties based on the timing of Executive’s separation from Executive’s current employer, and in any case conditional on such separation and on the Company’s determination that Executive is not restricted by any agreement between Executive and such employer from commencing employment with the Company (the “Effective Date”).
COMPASS THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • April 19th, 2021 • Compass Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”), dated as of April 14, 2021, is made between Compass Therapeutics, Inc., a Delaware corporation (including all wholly-owned subsidiaries of Compass Therapeutics, Inc., the “Company”), and Vered Bisker-Leib (the “Executive”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any offer letter, employment agreement or severance agreement.
COMPASS THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • April 19th, 2021 • Compass Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”), dated as of April 14, 2021, is made between Compass Therapeutics, Inc., a Delaware corporation (including all wholly-owned subsidiaries of Compass Therapeutics, Inc., the “Company”), and Thomas J. Schuetz, M.D., Ph.D. (the “Executive”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any offer letter, employment agreement or severance agreement.
EX-99.1 2 d625734dex991.htm EX-99.1 RESTORBIO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2020 • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 30th day of August, 2018, between resTORbio, Inc., a Delaware corporation (the “Company”), and Meredith S. Manning (the “Executive”) and is effective as of September 17, 2018 (the “Effective Date”).
RESTORBIO, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 18th, 2018 • resTORbio, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 30th day of August, 2018, between resTORbio, Inc., a Delaware corporation (the “Company”), and Meredith S. Manning (the “Executive”) and is effective as of September 17, 2018 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 24th, 2018 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made by and between Magenta Therapeutics, Inc., a Delaware corporation (the “Company”), and (the “Executive”), and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes, amends and restates in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any offer letter, employment agreement or severance agreement.
